28 August 2020 | News
This includes a study now progressing to Phase III that evaluates a novel monoclonal antibody as a treatment to neutralize SARS-CoV-2
Image Credit: shutterstock.com
US based DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry along with their CRO partner, Bestat Pharmaservices Corp. (Bestat) are building studies to support COVID-19 treatments and vaccines in Asia.
This includes a study now progressing to Phase III that evaluates a novel monoclonal antibody as a treatment to neutralize SARS-CoV-2 by binding to specific proteins found on the surface of the virus.
DSG’s platform enabled Bestat to rapidly build solutions for data collection, management and analysis, helping the clinical trials progress all the way from Phase I to Phase III in a very efficient and accelerated manner by ensuring clean data with real time data export and tools for analysis.
Bestat primarily leveraged the eCaseLink Designer module to build the studies in-house in just a few days, while maintaining the integrity for these demanding trials and timelines.
The eCaseLink Designer and EDC module helped create and manage the development of electronic clinical trial research questionnaires for the sponsors to effectively collect data from participating patients. Due to the success of these trials, Bestat has contracted with DSG to utilize the Interactive Response Technology (IRT) to manage Randomization and Drug Supply Management (RTSM) for the upcoming Phase III studies.